Myelotoxicity after 153Samarium-EDTMP treatment for painful bone metastases;Myelotoxicita po systémové radionuklidové terapii bolestivých kostních metastáz 153Samariem-EDTMP

Vnitrni Lekarstvi

Volumn 49, Issue 3, 2003, Pages 189-193

  Doležal, Jiří ^a   Vizd'a J ^a   Cermakova E ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Odd Vypocetni Tec Lekarska Fak UK   (Czech Republic)

Author keywords

153Samarium EDTMP; Bone metastases; Myelotoxicity

Indexed keywords

LEXIDRONAM SAMARIUM SM 153; RADIOPHARMACEUTICAL AGENT;

ANALGESIA; ARTICLE; BLOOD TOXICITY; BODY WEIGHT; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER LOCALIZATION; CANCER PATIENT; CLINICAL FEATURE; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; ERYTHROCYTE COUNT; HEMATOLOGY; HUMAN; KIDNEY CARCINOMA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PARAMETER; PROSTATE CANCER; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN, INTRACTABLE; PALLIATIVE CARE; PANCYTOPENIA; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SAMARIUM;

EID: 0344839047     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ahonen, A., Joensuu, H., Hiltunen, J. et al.: Samarium-153-EDTMP in bone metastases. J. Nucl. Biol. Med. 1994; 38 (4):123-127
2. Bayouth, J. E., Macey, D. J. et al.: Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J. Nucl. Med. 1994; 35 (1): 63 -69
3. Brenner, W., Kampen, W., Kampen, A. et al.: Skeletal uptake and Soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. J. Nucl. Med. 2001; 42: 230-236
4. Dafermou, A., Colamussi, P. et al.: A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur. J. Nucl. Med. 2001; 28 (7): 788-797
5. Droste, C., von Planta, M.: Memorix - vademekum lékaře. Scientia medica. Praha 1992: 210
6. Giammarile, F., Mognetti, T. et al.: Bone pain palliation with strontium-89 in cancer patients with bone metastases. Q. J. Nucl. Med. 2001; 45 (1): 78-83
7. Han, S. H., De Klerk, M. H. et al.: 186Re-Etidronate-efficacy of palliative radionuclide therapy for painful bone metastases. Q. J. Nucl. Med. 2001; 45 (1): 84-90
8. Harbert, J. C., Eckelman, W. C. et al.: Nuclear Medicine - Diagnosis and Therapy. Thieme Medical Publishers, Inc., New York. Georg Thieme Verlag, Stuttgart 1996
9. Holmes, R. A.: 153Sm-EDTMP: a potential therapy for bone cancer pain. Semin. Nucl. Med. 1992; 22 (1): 41-45
10. Kolesnikov-Gauthier, H., Carpentier, P. et al.: Evaluation of Toxicity and Efficacy of 186Re-Hydroxyethylidene Diphosphonate in Patients with Painful Bone Metastases of Prostate or Breast Cancer. J. Nucl. Med. 2000; 41 (10): 1689-1694
11. Lovera, C., Massardo, T., Galleguillos, M. C. et al.: Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with Samarium 153 ethylenediaminetetramethylenephosphate. Rev. Med. Chil. 1998;126 (8): 963-971
12. Mareš, J.: Psychologické přístupy ke zjišt'ování dětské bolesti. Čs. Pediat. 1994; 49 (4): 235-238
13. McEwan, A. J.: Use of radionuclides for the palliation of bone metastases. Semin. Radiat. Oncol. 2000; 10 (2): 103 -114
14. Miller, A. B., Hoogstraten, B. et al.: Reporting Results of Cancer Treatment. Cancer 1981; 47 (1): 207-214
15. Piffanelli, A., Dafermou, A. et al.: Radionuclide therapy for painful bone metastases. Q. J. Nucl. Med. 2001; 45 (1):100-105
16. Pons, F., Herranz, R., Gracia, A. et al.: Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur. J. Nucl. Med. 1997; 24 (10):1210-1214
17. van Regensburg, A. J., Alberts, A. S. et al.: Quantifying the Radiation Dosage to Individual Skeletal Lesions Treated with Samarium-153-EDTMP. J. Nucl. Med. 1998; 39 (12): 2110-2115
18. Resche, I., Chatal, J. F., Pecking, A. et al.: A dose-controlled study os 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur. J. Cancer 1997; 33 (10): 1583-1591
19. Sciuto, R., Tofani, A. et al.: Short- and Long-Term Effect of 186Re-1,1-Hydroxyethylidene Diphosphonate in the Treatment of Painful Bone Metastases. J. Nucl. Med. 2000; 41 (4): 647-654
20. Serafini, A. N.: Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int. J. Radiat. Oncol. Biol. Phys. 1994; 30 (5): 1187-1194
21. Serafini, A. N., Houston, S. J., Resche, I. et al.: Palliation of Pain Associated With Metastatic Bone Cancer Using Samarium-153 Lexidronam: A Double-Blind Placebo-Controlled Clinical Trial. J. Clin. Oncol. 1998; 16 (4): 1574-1581
22. Serafini, A. N.: Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer 2000; 88(12 Suppl.): 2934-2939
23. Serafini, A. N.: Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Q. J. Nucl. Med. 2001; 45 (1): 91-99
24. Serafini, A. N.: Therapy of metastatic bone pain. J. Nucl. Med. 2001; 42 (6): 895-906
25. Silberstein, E. B., Eugene, L. et al.: Painful osteoblastic metastases: the role of nuclear medicine. Oncology (Huntingt.) 2001; 15 (2): 157-163
26. Strzondala, W., Krajská, V.: Ionizující záření v terapii onkologické bolesti. Remedia 1995; 1-2 (5): 35-39
27. Vorlíček, J., Adam, Z. et al.: Paliativní medicina. Grada Publishing, Praha 1998: 27-65, 201-221